SOUTH SAN
FRANCISCO, USA and
VANCOUVER, Canada,
March 6,
2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA"
or the "Company") (NASDAQ: EPIX), a pharmaceutical company
that, prior to the discontinuation of its clinical trials and
development programs, has been focused on developing novel
therapies for the treatment of prostate cancer, is pleased to
announce the results of the votes on matters considered at its
Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting").
At the Meeting, the shareholders of the Company
(the "Shareholders") resolved to set the number of directors
of the Company at seven and re-elected to the board of directors,
by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella
Thorell, Alex Martin and
Sandy Zweifach to serve in office
until the next annual meeting or until their successors are duly
elected or appointed. Detailed results of the voting in respect of
the election of directors are as follows:
|
Nominee
|
Votes
For
|
% Votes
For
|
Votes
Withheld
|
% Votes
Withheld
|
|
David R.
Parkinson
|
9,131,148
|
98.83 %
|
108,123
|
1.17 %
|
|
Richard M.
Glickman
|
8,823,885
|
95.50 %
|
415,386
|
4.50 %
|
|
Franklin M.
Berger
|
8,807,588
|
95.33 %
|
431,683
|
4.67 %
|
|
Scott
Requadt
|
9,130,637
|
98.82 %
|
108,634
|
1.18 %
|
|
Marella
Thorell
|
9,135,934
|
98.88 %
|
103,337
|
1.12 %
|
|
Alex Martin
|
9,132,226
|
98.84 %
|
107,045
|
1.16 %
|
|
Sandy
Zweifach
|
9,112,900
|
98.63 %
|
126,371
|
1.37 %
|
At the Meeting, the Shareholders also approved:
(i) the re-appointment of Davidson & Company LLP, Chartered
Professional Accountants, as auditors of the Company; and (ii) on a
non-binding advisory basis, the compensation of the Company's named
executive officers.
Contact Information:
David
Wood
Chief Financial Officer, ESSA Pharma Inc.
T: 778-331-0962
E: dwood@essapharma.com
About ESSA Pharma Inc.
ESSA is a pharmaceutical company that was
previously focused on developing novel and proprietary therapies
for the treatment of patients with prostate cancer. For more
information, please visit www.essapharma.com.
View original
content:https://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-302394301.html
SOURCE ESSA Pharma Inc